The significance of this observation is supported by data demonstrating elevated mucosal epithelial expression of PD-L1 in IBD patients, and by the observation that pre-existing IBD predicts a risk for severe adverse events in cancer patients treated with immune checkpoint inhibitors (44–46). This evidence concerns the gene CD274 and inflammatory bowel disease.